IRLAB Therapeutics Management

Management criteria checks 2/4

IRLAB Therapeutics' CEO is Gunnar Olsson, appointed in Feb 2023, has a tenure of 1.25 years. directly owns 0.008% of the company’s shares, worth SEK45.59K. The average tenure of the management team and the board of directors is 11.3 years and 2 years respectively.

Key information

Gunnar Olsson

Chief executive officer

kr516.7k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	0.008%
Management average tenure	11.3yrs
Board average tenure	2yrs

Recent management updates

Recent updates

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

Jan 04

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Sep 21

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

CEO

Gunnar Olsson (70 yo)

1.3yrs

Tenure

kr516,666

Compensation

Mr. Gunnar Olsson has been a Director at IRLAB Therapeutics AB (publ) since 2017 and served as its Chairman since May 7, 2020 until February 2023 and is its Interim Chief Executive Officer since February 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gunnar Olsson	Interim CEO & Director	1.3yrs	kr516.67k	0.0077% SEK 45.6k
Nicholas Waters	Executive VP and Head of R&D	no data	kr1.70m	2.62% SEK 15.5m
Viktor Siewertz	Chief Financial Officer	7.3yrs	no data	0.45% SEK 2.7m
Clas Sonesson	Chief Scientific Officer	11.3yrs	no data	1.46% SEK 8.6m
Peder Svensson	Chief Information Officer and Director of Computational Chemistry & Biology	11.3yrs	no data	0.50% SEK 3.0m
Tove Bergenholt	Global IR & Communications	no data	no data	no data
Cecilia Stenberg	Head of Finance & Human Resource and Director of Accounting & Human Resources	11.3yrs	no data	0.70% SEK 4.2m
Joakim Tedroff	Chief Medical Officer	11.3yrs	kr5.00k	1.33% SEK 7.9m

11.3yrs

Average Tenure

61.5yo

Average Age

Experienced Management: IRLAB A's management team is seasoned and experienced (11.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gunnar Olsson	Interim CEO & Director	7.3yrs	kr516.67k	0.0077% SEK 45.6k
Rein Piir	Independent Director	8.3yrs	kr325.00k	0.081% SEK 477.7k
Carola Lemne	Independent Chairman of the Board	6.3yrs	kr310.00k	0.019% SEK 114.0k
Christer Nordstedt	Director	less than a year	no data	no data
Veronica Wallin	Independent Director	less than a year	no data	no data
Catharina Wallich	Independent Director	2yrs	kr326.67k	no data
Daniel Johnsson	Director	less than a year	no data	8.68% SEK 51.3m

2.0yrs

Average Tenure

61yo

Average Age

Experienced Board: IRLAB A's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

IRLAB Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

Recent updates

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Independent Vice Chairman of the Board recently bought kr330k worth of stock

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2021 Results on Apr 08, 2022

Independent Chairman recently bought kr74k worth of stock

Irlab Obtains Regulatory Approval to Conduct Phase IIb Study with Pirepemat

Independent Director recently bought kr112k worth of stock

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Chief Medical Officer recently sold kr1.8m worth of stock

Independent Director has left the company

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

IRLAB Announces First Patients in Europe Dosed in the clinical Phase IIb/III Study with Mesdopetam

New 90-day low: kr36.50

New 90-day low: kr38.55

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

IRLAB Therapeutics AB Presents New Data Indicating Mesdopetam Could Prevent Dyskinesia in Parkinson's Disease

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

IRLAB starts Phase IIb/III study with mesdopetam in the US

IRLAB Therapeutics AB Announces Appointments of Members of Nomination Committee

U.S. Food and Drug Administration Accepts IRLAB's Investigational New Drug Application

New 90-day high: kr46.50

New 90-day high - kr33.05

CEO